TD Cowen raised the price target for the Cullinan Oncology Inc. (NASDAQ:CGEM) stock to “an Outperform”. The rating was released on June 15, 2023, according to finviz.
The latest trade, Performances and Moving Averages give us the following Picture
The share price of Cullinan Oncology Inc. (NASDAQ:CGEM) raised 3.32% to close Friday’s market session at $9.96, higher as compared to yesterday’s close. The stock price fluctuated between $9.405 and $10.05 throughout the trading session with the volume trading being 680208 shares, which represented a significant variation when compared to the three months average volume of 244.38K shares. The firm’s stock price fluctuated -3.30% within the last five trades and -0.60% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price decreased -8.29% in the last 6 months and -21.57% was subtracted to its value over the previous 3 months. CGEM stock is trading at a margin of -6.52%, -5.56% and -7.89% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
As of the close of trading, CGEM deals in the Healthcare domain. The stock is trading -28.78 percent below its 52-week high and 27.99 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is -24.3. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does Cullinan Oncology Inc.’s Profitability and Valuation Ratios Tell Us About the Stock?
The stock’s market cap achieved a total value of $412.05 million as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. The firm managed a Price-to-Book ratio of 0.80, which equates the market value of a stock with its book value.
Is Insider Trading a Real Thing?
Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 1.00 percent of Cullinan Oncology Inc. shares are owned by insiders, and 82.30 percent are held by financial institutions. AHMED NADIM, the President and CEO at Cullinan Oncology Inc. (CGEM) has sold 759 shares of firm on Jun 28 at a price of $11.40 against the total amount of $8653.0. In another inside trade, Trigilio Jeffrey, Chief Financial Officer of Cullinan Oncology Inc. (NASDAQ:CGEM) sold 399 shares of the firm on Jun 20 for a total worth of $5163.0 at a price of $12.94. An inside trade which took place on Jun 20, Chief Medical Officer of Cullinan Oncology Inc. Jones Jeffrey Alan sold 387 shares of firm against total price of $5008.0 at the cost of $12.94 per share.